Coronary Arteriosclerosis Clinical Trial
Official title:
The Low HDL On Six Weeks Statin Therapy (LOW) Study
Verified date | September 2006 |
Source | Craigavon Area Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | United Kingdom: National Health Service |
Study type | Interventional |
Abnormal blood cholesterol levels increase the risk of developing, or dying from heart disease. It is well recognised that if "harmful" LDL cholesterol is high, and "protective" HDL cholesterol is low, this risk is increased. Drugs called statins are routinely used in patients with heart disease, are well tolerated, and decrease the harmful LDL cholesterol levels. However, statins only increase protective HDL cholesterol to a small extent. Some patients may thus benefit from additional medication to increase protective HDL-cholesterol further. One of the most effective drugs which can do this is nicotinic acid. This drug is well established having been available for over 30 years. Previous use has been limited by facial flushing in a large percentage of patients receiving the drug. However a new formulation called Niaspan is now available which is associated with much less flushing. Although many patients will have transient flushing, it is estimated that only 1 patient out of every 20 receiving the drug will have to discontinue treatment. We therefore propose, in patients with coronary artery disease and low HDL cholesterol despite being on a statin, to study the effect of Niaspan on HDL cholesterol and other lipid parameters, and to assess its tolerability.
Status | Active, not recruiting |
Enrollment | 60 |
Est. completion date | |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Persisting low HDL-C (<0.9mmol/l) on a full lipid profile result (which for inpatients should have been taken <24 hours after admission). - Objective diagnosis of coronary heart disease (previous biomarker proven MI, positive stress test, angiogram with at least one >50% diameter stenosis) - Established for at least 6 weeks on a “maintenance” dose of statin therapy (defined as Pravastatin 40mg, Simvastatin 40mg or Atorvastatin =10mg). The dose and type of statin should not be altered during the study period - Absence of concurrent major systemic illness (particularly liver or renal failure, or hypo or hyperthyroidism) Exclusion Criteria: - Previous use of Niaspan or other non-statin lipid lowering agent within the previous 12 weeks - Contraindications to Niaspan therapy - Participation in another medical trial within the previous 30days - Failure to obtain informed consent |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United Kingdom | Craigavon Cardiac Centre | Craigavon |
Lead Sponsor | Collaborator |
---|---|
Craigavon Area Hospital |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of patients achieving target HDL-C levels (defined as HDL-C >1.0mmol/l in males or >1.29mmol/l in females) after completion of the study protocol | |||
Secondary | Incidence and severity of flushing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00069654 -
Dietary Nitrate and Nitrite to Increase Nitric Oxide in Patients With Coronary Artery Disease
|
Phase 2 | |
Completed |
NCT02919124 -
Epicardial Echocardiography of Coronary Anastomoses Using the Echoclip Device
|
N/A | |
Recruiting |
NCT02639962 -
Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study
|
N/A | |
Completed |
NCT02494557 -
Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients
|
N/A | |
Recruiting |
NCT01466452 -
Antiplatelet Effect of Low Doses of Aspirin Taken Every 12 Hours in Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery
|
Phase 2 | |
Completed |
NCT01182428 -
XIENCE V: SPIRIT WOMEN Sub-study
|
Phase 4 | |
Completed |
NCT00368953 -
YUKON Choice Versus TAXUS Liberté in Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT00371891 -
Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
|
Phase 4 | |
Completed |
NCT00319449 -
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
|
Phase 4 | |
Completed |
NCT00091754 -
Atherosclerosis, Plaque and CVD in Communities
|
||
Completed |
NCT00069797 -
Epidemiology of Coronary Heart Disease in Men Aged 40 and Over
|
N/A | |
Completed |
NCT00037245 -
Androgens and Subclinical Atherosclerosis in Young Women - Ancillary to CARDIA
|
N/A | |
Completed |
NCT00024596 -
Family Heart Study - Subclinical Atherosclerosis Network (FHS-SCAN)
|
N/A | |
Completed |
NCT00006502 -
Myocardial Perfusion, Risk Factors, and Coronary Calcium
|
N/A | |
Completed |
NCT00006407 -
Sex Steroid Hormones and Risk of CHD in Women
|
N/A | |
Withdrawn |
NCT00006497 -
Long-Term Effects of Subclinical CAD on Cardiac Function
|
||
Completed |
NCT00006309 -
Pooling of Cohort Studies on Diet & Coronary Disease
|
N/A | |
Completed |
NCT00005269 -
Family Blood Pressure Program - GENOA
|
||
Completed |
NCT00000508 -
Stanford Coronary Risk Intervention Project (SCRIP)
|
Phase 3 | |
Completed |
NCT00005147 -
Epidemiology of Atherosclerosis
|
N/A |